Efficacy and safety of copanlisib in patients with relapsed or refractory marginal zone lymphoma

Marginal zone lymphoma (MZL) is challenging to treat, with many patients relapsing following initial treatment. We report the long-term efficacy and safety of copanlisib, a pan-class I phosphoinositide 3-kinase (PI3K) inhibitor, in the subset of 23 patients with relapsed/refractory MZL treated in th...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Blood Adv
Autori principali: Panayiotidis, Panayiotis, Follows, George A., Mollica, Luigina, Nagler, Arnon, Özcan, Muhit, Santoro, Armando, Stevens, Don, Trevarthen, David, Hiemeyer, Florian, Garcia-Vargas, Jose, Childs, Barrett H., Zinzani, Pier Luigi, Dreyling, Martin
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Hematology 2021
Soggetti:
Lymphoid Neoplasia
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7876879/
https://ncbi.nlm.nih.gov/pubmed/33560394
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020002910
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi